Reducing stigma and expanding methadone access in the U.S.: the Modernizing Opioid Treatment Access Act and beyond

Julio C Nunes1, Bryon Adinoff2

  • 1Department of Psychiatry, Yale University, New Haven, CT, USA.

Insights

The Modernizing Opioid Treatment Access (MOTA) Act could improve methadone access by allowing prescriptions via pharmacies. This reform aims to reduce stigma and increase equitable treatment for opioid use disorder.

Area of Science:

  • Public Health
  • Addiction Medicine
  • Healthcare Policy

Background:

  • Opioid treatment programs (OTPs) are crucial for methadone delivery but can create barriers to access and increase stigma.
  • Restrictive methadone regulations limit patient access, particularly in underserved communities.

Purpose of the Study:

  • To examine the implications, challenges, and policy directions of the Modernizing Opioid Treatment Access (MOTA) Act.
  • To assess the potential of the MOTA Act to improve equitable access to methadone via community pharmacies.

Main Methods:

  • This is a perspective piece, analyzing proposed legislative changes and existing evidence.
  • It reviews the role of OTPs, the impact of the COVID-19 pandemic on methadone access, and international pharmacy-dispensing models.

Main Results:

  • The MOTA Act proposes allowing addiction specialists to prescribe 30-day methadone doses through pharmacies, moving away from the traditional OTP model.
  • The COVID-19 pandemic demonstrated the safety of 30-day take-home methadone, and international models support pharmacy dispensing.

Conclusions:

  • Successful implementation of the MOTA Act requires addressing prescriber training, pharmacy participation, and insurance coverage.
  • Expanding methadone access through pharmacies can integrate addiction treatment into mainstream healthcare, potentially reducing stigma and improving outcomes for opioid use disorder.

Related Concept Videos

Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
437
Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
803
Opioid Analgesics: Morphine and Other Natural Cogeners01:20

Opioid Analgesics: Morphine and Other Natural Cogeners

Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
366
Drug Abuse and Addiction: Pharmacological Phenomena01:15

Drug Abuse and Addiction: Pharmacological Phenomena

Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
656
Opioid Receptors: Overview01:22

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
1.8K
Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
848